Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will be, maybe the hat and coffee mug. Friday’s increases more than justify the impulse buy.
You go all in when you know you are holding the best possible hand.
Thanks CUIN and others. The valuation comparisons to other companies and the likely revenue streams are truly incredible.
It’s a total shot in the dark, but I feel once this gets to NASDAQ and real deal concrete revenue starts flowing in this company is fairly valued at $8-9 bln - 100xs what it’s worth now. Just my opinion. I’d be kicking myself at that point if I hadn’t increased.
Tripled my investment today. Feeling great about it.
Got it on the double market cap - we now have Soundconcepts. At first I thought there was some calculation error based on the reverse split like those on the discount brokers earlier this week.
A corner bodega has more rev sure, but our future growth is higher than heaven.
Thanks, I saw a 2017 loss
Earnings? Can anyone assist? I’m driving ...
Martha Stewart next. Who knows, maybe Meek Mill and the Kraft family.
We can pass on Ja and the Fyre crew. Although they can certainly pull off a marketing campaign.
I kept looking for the actual link about NASDAQ status. Oh well, the music in the robots take over video was cool, very dramatic, even panic inducing if you are in the sales profession.
Alpert, I’ll give you credit where it’s due, but I don’t think you are right about this one starting Monday (assuming something actually happens on Monday). Maybe it’s a year behind schedule, but the train will eventually leave the station and turn into a rocket leaving the launch pad so buckle up like the man said.
Let ‘em hate and watch the money pile up. This could make the valuations real. Oracle + merger + Micro = $$$$
Not selling any time soon. Not until we’re in every CVS store, Scholls deal happens (hopefully with a large cash infusion), and at least one more produce gets FDA OTC approval.
Hey, at least we have OTC foot and knee, are in 200 CVS stores, and the SEC thing isn’t hanging over our heads.
But I understand the frustration, it’s totally justified. Shades of 2009 and the predicted approval “within weeks.” They were a lot more careful this time, but the result is similar. More waiting.
Emailed FDA again as well as MD US Senator Chris Van Hollen after learning BIEL wasn’t included in Innovation Challenge. Lots of anger nationwide at drug companies and the FDA over opiate deaths. This thing could play well in Congress. David and Goliath. US startup company desperately trying to sell more of their products in the good old US, FDA and (maybe but who knows for sure) Big Pharma holding them down, stuck in the swamp. At the very least someone needs to look into possible impropriety. The naive part of me still thinks that if the Commissioner reviewer the 510k personally, he could step in and rectify this situation.
Maybe someone else wants to shoot Van Hollen an email. Unlike the FDA he might have personal and political reasons to take up the cause.
I called the company and emailed the FDA contact person for the challenge as well as FDA Commissioner Gottlieb himself. The company confirmed the PR. You can find FDA emails in their directory from their main website and on the innovation challenge page. If this is the way it has to be so be it, but I want to make sure that the highest levels of the FDA are aware of this decision. I don’t want to let slide the misguided decision of some low level tunnel-visioned examiner stand without making a little noise.
Personally in total on BIEL that is, not talking SP for the year. This is a decade long thing, the yearly increase is for fund performance and such, BIEL is its own thing and IMO, we might just see .10 plus if several different catalysts hit in succession. CVS is huge! Let’s not forget that. This gives me renewed hope that Andy’s updates are playing out in real time. We would have killed for the product to be on CVS shelves. No we have it (albeit on a slow rollout basis) and some people are still worried or finding fault. Sure their quarterly numbers have been disappointing for the last year. But this company is about future growth. Many large companies saw huge, continuous SP increases (i.e., Tesla, Amazon) before they ever turned a profit.
Up 270%
Solid growth opportunities in the zoo market. Utica’s regional, sure, but imagine the National Zoo or the San Diego Zoo next. Animals with their own walkout videos! Pretty soon it won’t be just the rainforest exhibits and tigers with lines to get in.
UK, thanks so much for the corrections, this this very helpful. I stay away from FB, so thanks for sharing.
Definitely appreciate your local knowledge of the approval process.
I’m going to give you the benefit of the doubt. Here is my understanding:
1) The way that NHS reimbursement works in the UK is that you have to but it from the pharmacist counter to have it covered. So BIEL decided to pull it from the OTC shelves themselves. Now they are focusing on educating doctors and pharmacists. You can still buy it “OTC” on Amazon UK or whatever (it is legal to do so), but you won’t get NHS coverage if you do so. So yes, there was/is a drop in U.K.sales which should be temporary until the pharmacist/doctor angle gets going.
2) The regional issue I believe is a manufactured non-issue that Red cobbled together from unrelated sources with no context. He found some Leicestershire (not sure if that’s the right spelling/name) webpage which said something about a “review” of Actipatch in 2021. Red doesn’t know what that means and no one else does either so I’m ignoring it. For all we know that could be a re-review so that it can stay covered. As far as I’m concerned, because the NHS publicly approved it, it’s available in all the Shires, or will be after stocking/shipping, including in Barrowtown and Rivendell.
3) I wouldn’t worry about “share dumping” that word has been a bit of a scare tactic for years we don’t know how much the settlement is for. My personal opinion is that they wouldn’t fund it that way. Big players (cvs and Bayer just to name two) are interested in this and any amount (even the original amount) is chump change. Why wouldn’t they pay that for BIEL in exchange for slightly more favorable deal terms? Like Suge paying Pac’s bail money.
*Don’t get to put off by the board, people get territorial around here after years of obsessively watching this.
1) Your Boots link shows that ActiPatch can’t be orders online from Boots which seems consistent with BIELs strategy of pulling it from OTC to behind the pharmacist counter. As has been explained, this the way things work in the U.K. if you want efficient NHS reimbursement.
2) The NHS already has tons of real world data - in that Registry study. You may have the NHS confused with the FDA. Other countries are actually able to make clear and efficient decisions regarding healthcare without unreasonable delays and high political theater.
3) ActiPatch has been cleared for OTC use in the UK for several years and was recently approved for NHS reimbursement. Months of study went into their decision to approve it, including their own commissioning of an additional study and BIEL submitting that economic impact study. It seems highly unlikely if not impossible that they would reverse their decision.
Chin up Steve, keep calm and carry on. I know things aren’t ideal here, but this is really good news. I’m guessing you worked for a larger company. We appreciate your background and insight.
Yes, I noticed the zip code/SKU error.
Adds fuel to the fire for anyone who insists on keeping their head in the sand. Sorry for the mixed metaphor.
PS, zip codes near you might not have it. I’ve yet to find one in my area, and I’m in a large metropolitan area. But they may prioritized other areas.
Anyone is free to email Paul, you’ll get a prompt reply that there is indeed a soft rollout at CVS.
All the pieces fit.
1) Andy telegraphed this at the end of last year when he stated that they were in talks with a major chain that had a 25% market share of prescription. I speculated on this board in December 2017 that it was CVS based on a simple Google search for market share.
2) Now we have board members sending in receipts and pictures from CVS and calling stores (I called myself, the guy in Ohio knew right away what the Patch was, confirmed they had it and seemed annoyed that six other people had already called).
If people fabricated all the above, it would be fraudulent.
3) Many of us have emailed Paul and gotten a scripted response from management confirming the rollout.
What more do you need? It’s a pink sheet company, don’t expect an Apple-Style rollout or commercials during Monday night football before we have broader clearance.
Or you can go on believing that this is a deep state hoax or a vast right wing conspiracy.
I forgive you all for doubting, there’s a long history of setbacks with this company. Some of us need to put our fingers in the wounds to believe.
Yes Steve, thanks for your thoughtful posts. Never pissed me off. I laugh at the extreme negative posts here, they don’t piss me off either. They are very transparent as being misinformed, blatantly false, or coming from a very small group of disgruntled former employees.
Your posts are great and go a long way to keeping people informed. Up to date commentary on publicly available info. Makes the efficient market hum, even on a thinly traded pink sheet company. They can’t hold us back forever.
Don’t quit before the magic happens, for those of you who may have heard that suggestion before.
We are very likely to get Aetna FSA/HSA reimbursement for Actipatch and maybe full coverage for Recovery Rx. I have CVS Caremark with another insurer (previously with Aetna) and they are constantly trying to get you to do 90 day refills and mail order pharmacy in order to save money.
They want to save money and we know from the NHS study that Actipatch saves money in doctors visits, prescription, and likely surgeries as well.
Googled Protex and Actipatch and found a “Protex compression sleeve with Actipatch” at instacart site where it looks like it’s coming from CVS:
https://www.instacart.com/cvs/products/19193147-protex-compression-sleeve-with-actipatch-each
Could definitely be the “Ace Bandage” partnership we were envisioning, just with a company called Protex, whoever they are.
Great news! I think it may be worth it for people to drop by their local CVS, speak to a manager and then buy it when it comes in.
I made a round of calls and emails to the central product numbers for the major chains about a year ago. A grassroots effort in person could help their soft rollout and make BIEL great - again!
I just called they store, they do have the actipatch. The guy said they had six other calls. I started to describe it and he knew what I was saying right away. I hope people in pain buys them all, they restock and word spreads.
Here is my post from December of 2017. If this is the real deal, better late than never. I have not personally seen it on shelves, but IMO it’s a matter of time:
yankee55 Post# 116917
I agree, very interesting. I don’t know the current status of US insurance reimbursement, but it’s exciting to imagine some sort of smooth approval by Aetna of Actipatch as an FSA item if (and this is a big if) CVS starts carrying it on its shelves.
When AW said that they were in talks with a national drug store chain that handles 25% of prescriptions, I assumed it was Walgreens given the Boots connection. But when I Googled it, interestingly enough, CVS is at 24%, Walgreens at 17% or so.
Several months ago in an interview (I think it was Andy) said they were close to a deal with a major chain that had over 20% market share. It lined up with CVS’s share of the market. I’ll try to find my old post.
Chill out Red, they have big friends and patrons now (Bauer, NHS, Mundi, B. Braun, FDA, etc.) They are not on their own. BIELs allies won’t let them go under. Not to mention all the wealthy people including the Whealans that have been keeping this company on oxygen and a respirator for years.
This device will save lives in the opiate epidemic. Many of us have been personally affected and are struggling right now. It won’t be a substitute for addicts, but it could reduce addiction in whole category of people who were prescribed the wrong thing and are now in trouble. It’s a viable and preventative alternative for all kinds of pain. We deserve that FDA award. What a story if BIEL gets it.
Correct! The original ask was cut in half because of a different court decision that affected the amount of disgorgement that the SEC could ask for. If I’m correct, the 25 percent wound end being 400-500k. But it could be event lower given the general mood of the administration. Look at what they did to the CFPB.
Very correct JGD. This is what I’m talking about, we have a very informed board.
Well said JGD! As many have predicted, it looks like the SEC became much more flexible after the Supreme Court decision. Imagine having a backlog of cases that have to be re-litigated in front of newly blessed ALJs in order to comply with the Appointments Clause. They were likely to prioritize enforcement cases against bigger fish. The “harm” here is so convoluted I couldn’t imagine being an enforcement atty at the SEC and arguing to higher ups that we need to keep going after little old BIEL because of incorrect and borderline decisions that a little pink sheet company only made after they got bad advice from the professionals they hired in their early days.
Contrary to what stock had always said, this is not a death blow to the company. Many companies pay fines and keep it moving. I’m guessing they settled for half or less than the original ask.
Great news to have this cloud removed! Feeling a big I told you so vibe on behalf of the real longs who read the filings, appeals, Supreme Court decisions and law blogs.
This is great news IMO. I wonder if they may decide to drop some cases that they don’t consider high priority. Their legal situation is much brighter after the recent decisions by the Court and the Commission. At minimum it gives BIEL more time to come up with the money to pay. It may also increase the likelihood of a settlement for much less than the current $780K or whatever it is.
I think this more than makes up for the AS increase. I thought the AS was inevitable in the short term, but Lucia and the Sup. Court could easily have come out different. If that original penalty was enforced right away before all of the recent great news, I’m not sure the company would have come out intact.
Instead, we are riding high and I can’t wait for the next big PR or two. It could be anything, but my bet is FDA clearance and huge Bayer deal.
I agree with everything you wrote in this post, it is supported in today’s opinion and in BIEL’s SEC docket. My guess is a final settlement is under $767K. Why not $383K?
Check out pages 12 and 13 of the majority’s opinion, including the footnotes on page 13. Lucia gets a new hearing by a properly appointed ALJ. Even better, the court says it can’t be Elliot again, who if memory serves happens to be the same ALJ that heard BIEL’s case. He gets this relief because he asked for it in a timely manner.
I read that to mean that this may not affect past judgments, but hopefully it will apply to us since BIEL’s opinion was made in a timely manner while the Lucia matter made its way through the courts.
The footnote on page 13 acknowledges that the SEC (the “commission” itself not and individual officer) tried to instantly approve the appointment of all its ALJs so that it would meet the requirements of the Appt. Clause, but the Court says it will not address that. So in effect, it seems to ignore that and says Lucia’s case still needs to be heard by a properly appointed ALJ.
The million dollar question is whether we get the same treatment as Lucia.
Here’s my bottom like (just my opinion of course): This is the exact ruling we were looking for short the case just being dismissed/dropped. Worst case scenario, we go through the hearing all over again and get a harsher sanction (this is theoretically possible). More likely they would want to settle given the backlog. Cut the baby in half and take 50% of the reduced amount?
Thanks, this is not at all surprising and doesn’t give me any cause for concern. In a perfect world, they wouldn’t need the AS increase from all the money rolling in.
However, I have been expecting this (as I’m sure others have) and am surprised that they went this long without an increase. An educated guess is that they need this to ramp up production (their orders to their manufacturers in China [if memory serves, that’s where they are]) along with their other ongoing costs (510k application, legal costs related to the SEC matter, redesign of packaging including KT tape, etc.)
Looks like full clearance and Dr. Scholl’s/Bayer may happen by the end of the summer and then the 5 bln increase will be only a blip on the trajectory of BIEL’s SP.
As filings go, this is much better than a RS, and the increase is relatively modest. AW has said NHS should increase UK sales by multiples, so that may make this AS increase the last one. Assuming they don’t have a Tesla issue of their costs outpacing their profits, NHS sales allow them to meet their ongoing expenses and they turn profitable by a few dollars.
That’s always a valid concern when OTCs go on a run. However, I think a key point is that hardly any investors know about this. When FDA approval and Bauer come through (as the CEO and others at the company have suggested in interviews as highly likely), in my opinion this will climb. It’s hard to imagine too many financial advisers pitching a sub penny company, but it could be a very different story if this hits .01 or .10.